Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference Print
GlobeNewswire
Tuesday, 07 January 2014 01:30

CARMIEL, Israel--Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 12:00 PM, Pacific Time.

The conference will be held at the Westin St. Francis Union Square Hotel in San Francisco on January 13-16, 2014.  A live webcast of the presentation will be available at www.protalix.com on the event calendar page.  A replay will be archived and available after the conclusion of the presentation for 90 days.

About Protalix

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx┬«. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013, and by the regulatory authorities of other countries. Marketing applications for taliglucerase alfa have been filed in additional territories as well.  Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel and Brazil, where Protalix retains full rights. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel┬«) for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, Chrohn's disease, colitis, psoriasis and

other autoimmune and

Error. Page cannot be displayed. Please contact your service provider for more details. (11)

inflammatory disorders; PRX-110 for the treatment of Cystic Fibrosis; PRX-107 for the treatment of emphysema due to hereditary alpha1-antitrypsin deficiency; and others.

CONTACT: Investor Contact          Marcy Nanus          The Trout Group, LLC          646-378-2927          mnanus@troutgroup.com                    Media Contact          Kari Watson          MacDougall Biomedical Communications          781-235-3060          kwatson@macbiocom.com



BiomedReports is not paid or compensated by newswires to disseminate or report news and
developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1